Accentia Biopharmace (ABPI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 09/30
(Values in U.S. thousands)
| 09-2012 | 09-2011 | 09-2010 | 09-2009 | 09-2008 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,188 | -15,653 | -48,211 | -5,718 | -60,792 |
| Depreciation Amortization | 250 | 562 | 987 | 2,002 | 11,242 |
| Accounts receivable | 863 | 71 | 1,478 | 1,633 | 2,723 |
| Accounts payable and accrued liabilities | 466 | 480 | -741 | 1,849 | -2,960 |
| Other Working Capital | 6,671 | 2,995 | 6,239 | 11,503 | -1,744 |
| Other Operating Activity | 316 | 18,487 | 39,828 | -13,201 | 26,919 |
| Operating Cash Flow | $-622 | $6,942 | $-420 | $-1,932 | $-24,610 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -98 | -789 | -72 | N/A | -70 |
| Net Acquisitions | N/A | N/A | N/A | N/A | -200 |
| Other Investing Activity | 5,500 | 0 | 0 | 0 | 1,983 |
| Investing Cash Flow | $5,402 | $-789 | $-72 | $N/A | $1,713 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 3,500 | 2,250 | N/A | N/A | 8,079 |
| Debt Issued | N/A | 7,353 | 640 | 1,250 | 8,870 |
| Common Stock Issued | 805 | 6 | N/A | N/A | 4,641 |
| Other Financing Activity | -3,689 | -2,842 | 86 | -132 | 913 |
| Financing Cash Flow | $616 | $6,767 | $726 | $1,118 | $22,504 |
| Beginning Cash Position | 421 | 559 | 325 | 1,139 | 1,623 |
| End Cash Position | 129 | 421 | 559 | 325 | 1,229 |
| Net Cash Flow | $-291 | $-138 | $233 | $-814 | $-394 |
| Free Cash Flow | |||||
| Operating Cash Flow | -622 | 6,942 | -420 | -1,932 | -24,610 |
| Capital Expenditure | -98 | -789 | -72 | N/A | -88 |
| Free Cash Flow | -720 | 6,153 | -492 | -1,932 | -24,698 |